Hepatic impairment No dose adjustment is needed in clients with gentle or reasonable (Child-Pugh A or B) hepatic impairment (see part 5.2). Exposure to midostaurin and its active metabolite CGP62221 is considerably reduced in patients with intense hepatic impairment than that in sufferers with regular hepatic functionality (see part 5. https://anthonya863nsv6.blogdeazar.com/profile